These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

993 related articles for article (PubMed ID: 15105298)

  • 1. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation.
    Dyck JR; Cheng JF; Stanley WC; Barr R; Chandler MP; Brown S; Wallace D; Arrhenius T; Harmon C; Yang G; Nadzan AM; Lopaschuk GD
    Circ Res; 2004 May; 94(9):e78-84. PubMed ID: 15105298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors.
    Cheng JF; Chen M; Wallace D; Tith S; Haramura M; Liu B; Mak CC; Arrhenius T; Reily S; Brown S; Thorn V; Harmon C; Barr R; Dyck JR; Lopaschuk GD; Nadzan AM
    J Med Chem; 2006 Mar; 49(5):1517-25. PubMed ID: 16509570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of heterocyclic malonyl-CoA decarboxylase inhibitors.
    Cheng JF; Chen M; Liu B; Hou Z; Arrhenius T; Nadzan AM
    Bioorg Med Chem Lett; 2006 Feb; 16(3):695-700. PubMed ID: 16257202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury.
    Dyck JR; Hopkins TA; Bonnet S; Michelakis ED; Young ME; Watanabe M; Kawase Y; Jishage K; Lopaschuk GD
    Circulation; 2006 Oct; 114(16):1721-8. PubMed ID: 17030679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting malonyl CoA inhibition of mitochondrial fatty acid uptake as an approach to treat cardiac ischemia/reperfusion.
    Ussher JR; Lopaschuk GD
    Basic Res Cardiol; 2009 Mar; 104(2):203-10. PubMed ID: 19242641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.
    Lopaschuk GD; Barr R; Thomas PD; Dyck JR
    Circ Res; 2003 Aug; 93(3):e33-7. PubMed ID: 12869392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The malonyl CoA axis as a potential target for treating ischaemic heart disease.
    Ussher JR; Lopaschuk GD
    Cardiovasc Res; 2008 Jul; 79(2):259-68. PubMed ID: 18499682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malonyl CoA control of fatty acid oxidation in the newborn heart in response to increased fatty acid supply.
    Onay-Besikci A; Sambandam N
    Can J Physiol Pharmacol; 2006 Nov; 84(11):1215-22. PubMed ID: 17218986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malonyl-CoA decarboxylase inhibition as a novel approach to treat ischemic heart disease.
    Lopaschuk GD; Stanley WC
    Cardiovasc Drugs Ther; 2006 Dec; 20(6):433-9. PubMed ID: 17136490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased cardiac fatty acid uptake with dobutamine infusion in swine is accompanied by a decrease in malonyl CoA levels.
    Hall JL; Lopaschuk GD; Barr A; Bringas J; Pizzurro RD; Stanley WC
    Cardiovasc Res; 1996 Nov; 32(5):879-85. PubMed ID: 8944819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of rat liver malonyl-CoA decarboxylase and the study of its role in regulating fatty acid metabolism.
    Dyck JR; Berthiaume LG; Thomas PD; Kantor PF; Barr AJ; Barr R; Singh D; Hopkins TA; Voilley N; Prentki M; Lopaschuk GD
    Biochem J; 2000 Sep; 350 Pt 2(Pt 2):599-608. PubMed ID: 10947976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts.
    Lopaschuk GD; Wambolt RB; Barr RL
    J Pharmacol Exp Ther; 1993 Jan; 264(1):135-44. PubMed ID: 8380856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells.
    Zhou W; Tu Y; Simpson PJ; Kuhajda FP
    Oncogene; 2009 Aug; 28(33):2979-87. PubMed ID: 19543323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel partial fatty acid oxidation inhibitor decreases myocardial oxygen consumption and improves cardiac efficiency in demand-induced ischemic heart.
    Wu L; Belardinelli L; Fraser H
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):372-9. PubMed ID: 18427280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent and orally available malonyl-CoA decarboxylase inhibitors as cardioprotective agents.
    Cheng JF; Huang Y; Penuliar R; Nishimoto M; Liu L; Arrhenius T; Yang G; O'leary E; Barbosa M; Barr R; Dyck JR; Lopaschuk GD; Nadzan AM
    J Med Chem; 2006 Jul; 49(14):4055-8. PubMed ID: 16821767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    Kantor PF; Lucien A; Kozak R; Lopaschuk GD
    Circ Res; 2000 Mar; 86(5):580-8. PubMed ID: 10720420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion.
    Wang P; Fraser H; Lloyd SG; McVeigh JJ; Belardinelli L; Chatham JC
    J Pharmacol Exp Ther; 2007 Apr; 321(1):213-20. PubMed ID: 17202401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury.
    Ussher JR; Wang W; Gandhi M; Keung W; Samokhvalov V; Oka T; Wagg CS; Jaswal JS; Harris RA; Clanachan AS; Dyck JR; Lopaschuk GD
    Cardiovasc Res; 2012 May; 94(2):359-69. PubMed ID: 22436846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High rates of residual fatty acid oxidation during mild ischemia decrease cardiac work and efficiency.
    Folmes CD; Sowah D; Clanachan AS; Lopaschuk GD
    J Mol Cell Cardiol; 2009 Jul; 47(1):142-8. PubMed ID: 19303418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia.
    Stanley WC; Morgan EE; Huang H; McElfresh TA; Sterk JP; Okere IC; Chandler MP; Cheng J; Dyck JR; Lopaschuk GD
    Am J Physiol Heart Circ Physiol; 2005 Dec; 289(6):H2304-9. PubMed ID: 16100246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.